Imaging Atherosclerotic Plaque Inflammation With [ <sup>18</sup> F]-Fluorodeoxyglucose Positron Emission Tomography

DOI Web Site 被引用文献49件
  • J.H.F. Rudd
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • E.A. Warburton
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • T.D. Fryer
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • H.A. Jones
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • J.C. Clark
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • N. Antoun
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • P. Johnström
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • A.P. Davenport
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • P.J. Kirkpatrick
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • B.N. Arch
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • J.D. Pickard
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.
  • P.L. Weissberg
    From the Division of Cardiovascular Medicine (J.H.F.R., H.A.J., P.L.W.), Division of Stroke Medicine (E.A.W.), Wolfson Brain Imaging Centre (T.D.F., J.C.C., J.D.P.), Department of Radiology (N.A.), Clinical Pharmacology Unit (P.J., A.P.D.), Division of Neurosurgery (P.J.K.), and Centre for Applied Medical Statistics (B.N.A), University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK.

書誌事項

公開日
2002-06-11
DOI
  • 10.1161/01.cir.0000020548.60110.76
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Background</jats:italic> </jats:bold> — </jats:italic> </jats:bold> Atherosclerotic plaque rupture is usually a consequence of inflammatory cell activity within the plaque. Current imaging techniques provide anatomic data but no indication of plaque inflammation. The glucose analogue [ <jats:sup>18</jats:sup> F]-fluorodeoxyglucose ( <jats:sup>18</jats:sup> FDG) can be used to image inflammatory cell activity non-invasively by PET. In this study we tested whether <jats:sup>18</jats:sup> FDG-PET imaging can identify inflammation within carotid artery atherosclerotic plaques. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Methods and Results</jats:italic> </jats:bold> — </jats:italic> </jats:bold> Eight patients with symptomatic carotid atherosclerosis were imaged using <jats:sup>18</jats:sup> FDG-PET and co-registered CT. Symptomatic carotid plaques were visible in <jats:sup>18</jats:sup> FDG-PET images acquired 3 hours post- <jats:sup>18</jats:sup> FDG injection. The estimated net <jats:sup>18</jats:sup> FDG accumulation rate (plaque/integral plasma) in symptomatic lesions was 27% higher than in contralateral asymptomatic lesions. There was no measurable <jats:sup>18</jats:sup> FDG uptake into normal carotid arteries. Autoradiography of excised plaques confirmed accumulation of deoxyglucose in macrophage-rich areas of the plaque. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Conclusions</jats:italic> </jats:bold> — </jats:italic> </jats:bold> This study demonstrates that atherosclerotic plaque inflammation can be imaged with <jats:sup>18</jats:sup> FDG-PET, and that symptomatic, unstable plaques accumulate more <jats:sup>18</jats:sup> FDG than asymptomatic lesions. </jats:p>

収録刊行物

  • Circulation

    Circulation 105 (23), 2708-2711, 2002-06-11

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (49)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ